Aligos Therapeutics (ALGS) Net Income towards Common Stockholders (2021 - 2025)
Historic Net Income towards Common Stockholders for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$31.5 million.
- Aligos Therapeutics' Net Income towards Common Stockholders fell 6375.2% to -$31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.5 million, marking a year-over-year decrease of 1235.69%. This contributed to the annual value of -$131.2 million for FY2024, which is 4964.93% down from last year.
- As of Q3 2025, Aligos Therapeutics' Net Income towards Common Stockholders stood at -$31.5 million, which was down 6375.2% from -$15.9 million recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Net Income towards Common Stockholders registered a high of $43.1 million during Q1 2025, and its lowest value of -$82.1 million during Q4 2024.
- For the 5-year period, Aligos Therapeutics' Net Income towards Common Stockholders averaged around -$23.6 million, with its median value being -$23.0 million (2023).
- Examining YoY changes over the last 5 years, Aligos Therapeutics' Net Income towards Common Stockholders showed a top increase of 22359.23% in 2025 and a maximum decrease of 41343.61% in 2025.
- Aligos Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$37.7 million in 2021, then skyrocketed by 41.97% to -$21.9 million in 2022, then decreased by 27.44% to -$27.9 million in 2023, then crashed by 194.53% to -$82.1 million in 2024, then skyrocketed by 61.61% to -$31.5 million in 2025.
- Its last three reported values are -$31.5 million in Q3 2025, -$15.9 million for Q2 2025, and $43.1 million during Q1 2025.